title: Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer.
abstract: The goal of this study is to evaluate a new targeting strategy to improve nanomedicine delivery to breast cancer cells that survive prior exposure to chemotherapy. These cells are particularly difficult to treat because they often develop drug resistance by upregulation of chemoresistant factors such as clusterin and should be preferably eradicated before they further spread out. In this study, the surface endocytotic receptor megalin was studied for the first time for targeted delivery of anti-clusterin small-interfering RNAs (siRNAs) to these chemo-treated cells. Lipid-polyethylenimine hybrid nanocarriers decorated with apolipoprotein E (Ap-LPNs) were developed for this purpose. Using immunoblotting, we demonstrated induction of both megalin and clusterin in MCF-7 cells by previous paclitaxel treatment. The siRNA transfection of these megalin-rich chemo-treated cancer cells was improved by three-fold when the siRNAs were delivered by Ap-LPNs. This trend was translatable into enhanced clusterin knockdown and improved chemosensitization to subsequent paclitaxel treatment (both p<0.05 versus uncoated LPNs). This proof-of-principle study has validated a novel "chemoresistance-targeting" strategy for siRNA delivery to the cancer cell subpopulation that begins to acquire chemoresistance and is in strong need for chemosensitization.
authors.affiliation: Department of Pharmaceutical Sciences, Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, PA 19140, USA.
authors.forename: Hui Yi
authors.initials: HY
authors.lastname: Xue
authors.forename: Ho Lun
authors.initials: HL
authors.lastname: Wong
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D001057:Apolipoproteins E / Q000737:chemistry; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D051152:Clusterin / Q000235:genetics*; D019008:Drug Resistance, Neoplasm; D005260:Female; D055785:Gene Knockdown Techniques; D006801:Humans; D008055:Lipids / Q000737:chemistry; D026561:Low Density Lipoprotein Receptor-Related Protein-2 / Q000235:genetics*; D053758:Nanoparticles; D017239:Paclitaxel / Q000494:pharmacology*; D011094:Polyethyleneimine / Q000737:chemistry; D034741:RNA, Small Interfering / Q000008:administration & dosage*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D001057:Apolipoproteins E; D051152:Clusterin; D008055:Lipids; D026561:Low Density Lipoprotein Receptor-Related Protein-2; D034741:RNA, Small Interfering; D011094:Polyethyleneimine; D017239:Paclitaxel